Masivet 150mg Tablets (pack of 30)
|Prescription Type||POM-V (Written prescription required)|
MASIVET® is a tablet containing mastinib, which belongs to a class of medicines with an anticancer action.
It is prescribed to treat dogs with severe mast-cell tumours.
MASIVET® is only available with a prescription from your veterinary surgeon.
The most up to date Summary of Product Characteristics for this authorised veterinary medicine can be viewed here.
Mastivet contains mastinib.
Masitinib is a protein-tyrosine kinase inhibitor which, in vitro, potently and selectively inhibits the mutated form, in the juxtamembrane (JM) region, of the c-kit receptor. It also inhibits the Platelet Derived Growth Factor (PDGF) receptor and the Fibroblast Growth Factor Receptor (FGFR3). In the pivotal clinical field study, dogs of various breeds, ranging in age from two to seventeen years, were randomly treated with Masivet at a dose of 12.5 mg/kg or with a placebo. In dogs with nonresectable mast cell tumours, Grade 2 or 3, expressing a mutated tyrosine kinase c-kit receptor, treatment with Masivet showed a significantly longer Time-to-Tumour Progression (TTP) with a median of 241 days as compared to 83 days for placebo. Response to treatment with masitinib was expressed as stable disease; i.e. static, partial or complete response. Masitinib treatment should only be used in dogs with non-resectable mast cell tumours, which express the mutated c-kit tyrosine kinase receptor. The presence of a mutated tyrosine kinase c-kit receptor must be confirmed prior to treatment.
PackagingBottle with child-resistant closure cap containing 30 Masivet 150mg film-coated tablets.
Masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
Pig liver powder
Titanium dioxide (E171)
Sunset yellow (E110) aluminium lake.
MASIVET® is a prescription product and must be applied according to the instructions by your veterinary surgeon.
Please read the product leaflet thoroughly before applying to your pet.
MARKETING AUTHORISATION HOLDER
AB Science S.A.
3 avenue George V
MARKETING AUTHORISATION NUMBER(S)
The European Medicines Agency Summary for the Public for this medicine can be viewed here.